A new study finds that elevated levels of Lp(a) may increase the risk of death from cardiovascular disease in some patie ...

CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

Elevated lipoprotein(a) [Lp(a)] levels are genetically determined and often lead to premature heart attacks and other vascular diseases. Yet in outpatient care, this serious risk frequently goes ...

Even after stopping treatment with the novel small interfering RNA (siRNA) olpasiran (Amgen), patients experience sustained lowering of lipoprotein(a) for almost 1 year, according to new phase II data ...

CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a major ...